Rapid Diagnostic Technology for AUGIB Based on Analysis of VOCs in Exhaled Breath

Launched by BEIJING 302 HOSPITAL · Mar 10, 2025

Keywords

ClinConnect Summary

This clinical trial is looking to develop a new, quick, and non-invasive way to diagnose acute upper gastrointestinal bleeding (AUGIB) by analyzing the chemicals in a person's breath. Researchers will study patients who have been confirmed to have AUGIB and divide them into three groups based on the severity of their bleeding: no bleeding, minor bleeding, and major bleeding. The goal is to create a model that can accurately predict the presence and severity of bleeding by examining specific compounds in the breath. This method could help doctors diagnose patients faster, especially in emergency situations where traditional methods may not be as effective.

To participate in the trial, individuals must be at least 18 years old and show signs of AUGIB, such as vomiting blood or having black, tarry stools. Participants will need to fast for 4 hours before the test and provide written consent to take part. However, people with certain medical conditions, recent lung infections, or who are pregnant may not be eligible. The trial is not yet recruiting participants, but it aims to improve how doctors can quickly and accurately diagnose gastrointestinal bleeding, ultimately helping patients receive the care they need sooner.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years;
• • 2. Clinical suspicion of AUGIB (e.g., hematemesis, melena);
• • 3. Fasting ≥4 hours;
• • 4. Signed informed consent.
• Exclusion Criteria:
• • 1. Severe pulmonary dysfunction or recent lung infection (within 1 week);
• • 2. Cardiac/renal failure or disseminated intravascular coagulation;
• • 3. Contraindications to endoscopy;
• • 4. High-risk conditions (e.g., massive ascites);
• • 5. Alcohol consumption within 24 hours;
• • 6. Pregnancy.